0
0
9/12/22 at 10:39am
Organization
Labiotech.eu
Author
Jim Cornall
35 words
0
Comments
Shasqi says it has opened the phase 2 part of its phase 1/2a clinical study to further assess SQ3370 in anthracycline-naïve patients.
You are the first to view
https://www.labiotech.eu/trends-news/shasqi-phase-2-solid-tumor-study/
Create an account
or login to join the discussion